Results and analysis of the application of a consistent targeted therapy in patients with metastatic renal cell carcinoma in Moscow (for the period from June 2005 to July 2015)

Background. This article is a personal experience of a sequential targeted therapy of tyrosine kinase inhibitors for the period from June 2005 to July 2015.

Objective: evaluation of the results of the consistent application of targeted therapies in Moscow in this period.

Materials and methods. A retrospective analysis of cumulative progression-free survival in 220 patients of 354 patients with mRCC were studied. Was used Statistica 10.0 program.

Results. This article presents an analysis of the effectiveness of treatment and survival of patients receiving this therapy in cancer institutions Department of Health in Moscow.

Conclusion. Using of targeted therapy scheme sunitinib → sorafenib, we see no significant difference sVBP compared with scheme sorafenib → sunitinib with two lines ofsequential therapy tyrosine kinase inhibitors (16.9 and 18.2 months). According to our data total progression-free survival terms as applied to the 1st line of therapy tirosine kinase inhibitors (sunitinib and sorafenib), followed by the appointment pazopanib in the 2nd line (12.5 and 14.4 months) and pazopanib in 1st line followed by the appointment tirazinkinaz inhibitors (sunitinib and sorafenib) in the 2nd line (12.50 and 11.56 months) compared to the preliminary results of a multicenter randomized trial expected SWITCH II also not statistically different.